XML 74 R41.htm IDEA: XBRL DOCUMENT v3.25.0.1
Fair Value of Financial Instruments (Tables)
12 Months Ended
Dec. 31, 2024
Fair Value Disclosures [Abstract]  
Schedule of Company's Financial Instruments by Significant Investment Category Measured at Fair Value on a Recurring Basis Within the Fair Value Hierarchy

The following tables summarize the Company's assets and liabilities measured at fair value on a recurring basis within the fair value hierarchy as of December 31, 2024 (in thousands):

 

 

 

 

 

 

Fair Value Measurements At Reporting Date Using

 

 

 

Total

 

 

Quoted Prices in Active Markets For Identical Assets (Level 1)

 

 

Significant Other Observable Inputs (Level 2)

 

 

Significant Unobservable Inputs (Level 3)

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents—money market funds

 

$

141,942

 

 

$

141,942

 

 

$

 

 

$

 

Cash equivalents—U.S. treasury securities

 

 

2,990

 

 

 

 

 

 

2,990

 

 

 

 

Short-term investments—U.S. treasury securities

 

 

126,146

 

 

 

 

 

 

126,146

 

 

 

 

Total assets measured at fair value

 

$

271,078

 

 

$

141,942

 

 

$

129,136

 

 

$

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

Warrant liabilities

 

$

274

 

 

$

 

 

$

 

 

$

274

 

Contingent consideration

 

 

5,600

 

 

 

 

 

 

 

 

 

5,600

 

Total liabilities measured at fair value

 

$

5,874

 

 

$

 

 

$

 

 

$

5,874

 

 

The following tables summarize the Company’s assets and liabilities measured at fair value on a recurring basis within the fair value hierarchy as of December 31, 2023 (in thousands):

 

 

 

 

 

 

Fair Value Measurements At Reporting Date Using

 

 

 

Total

 

 

Quoted Prices in Active Markets For Identical Assets (Level 1)

 

 

Significant Other Observable Inputs (Level 2)

 

 

Significant Unobservable Inputs (Level 3)

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents—money market funds

 

$

35,385

 

 

$

35,385

 

 

$

 

 

$

 

Short-term investments—U.S. treasury securities

 

 

63,191

 

 

 

 

 

 

63,191

 

 

 

 

Total assets measured at fair value

 

$

98,576

 

 

$

35,385

 

 

$

63,191

 

 

$

 

Schedule of Available-for-Sale Securities Reconciliation

The following table summarizes available-for-sale-securities (in thousands):

 

 

 

 

 

 

 

 

As of December 31, 2024

 

 

 

Maturity (in years)

 

Amortized Cost

 

 

Unrealized Gains

 

 

Unrealized Losses

 

 

Estimated Fair Value

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents—money market funds

 

 

 

$

141,942

 

 

$

 

 

$

 

 

$

141,942

 

Cash equivalents—U.S. treasury securities

 

 

 

 

2,989

 

 

 

1

 

 

 

 

 

 

2,990

 

Short-term investments—U.S. treasury securities

 

1 or less

 

 

125,975

 

 

 

171

 

 

 

 

 

 

126,146

 

Total assets measured at fair value

 

 

 

$

270,906

 

 

$

172

 

 

$

 

 

$

271,078

 

 

 

 

 

 

 

 

 

As of December 31, 2023

 

 

 

Maturity (in years)

 

Amortized Cost

 

 

Unrealized Gains

 

 

Unrealized Losses

 

 

Estimated Fair Value

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents—money market funds

 

 

 

$

35,385

 

 

$

 

 

$

 

 

$

35,385

 

Short-term investments—U.S. treasury securities

 

1 or less

 

 

63,169

 

 

 

22

 

 

 

 

 

 

63,191

 

Total assets measured at fair value

 

 

 

$

98,554

 

 

$

22

 

 

$

 

 

$

98,576

 

Schedule of Liabilities Measured at Fair Value on a Recurring Basis

The following table presents information about the Company's Level 3 liabilities that are measured at fair value on a recurring basis:

 

 

Warrant Liabilities

 

 

Contingent Consideration

 

Balance at December 31, 2023

$

 

 

$

 

Fair value of warrant liabilities assumed in connection with the Merger

 

906

 

 

 

 

Fair value of contingent consideration recorded in connection with the acquisition of Sengenics

 

 

 

 

5,600

 

Change in fair value

 

(632

)

 

 

 

Balance at December 31, 2024

$

274

 

 

$

5,600

 

 

Schedule of Warrants Liabilities and Contingent Consideration Following the Closing Date, and as of December 31, 2024, the Public Warrants were no longer publicly traded (see Note 2), so the Warrants were valued using a binomial lattice model (a special case of the income approach), using the following Level 3 inputs:

 

 

 

December 31, 2024

 

 

January 5, 2024

 

Volatility

 

 

75.0

%

 

 

70.2

%

Risk-free rate

 

 

4.18

%

 

 

4.20

%

Warrant term

 

 

1.7

 

 

 

2.7

 

Contingent consideration

The contingent consideration was valued using a Monte Carlo simulation as of November 21, 2024 and December 31, 2024, using the following Level 3 inputs:

 

 

 

December 31, 2024

 

 

November 21, 2024

 

Revenue volatility

 

 

15

%

 

 

15

%

Risk-free rate

 

 

4.30

%

 

 

4.30

%

Expected Term

 

 

3.5

 

 

 

3.6

 

Summary of Amounts Transferred into Level 3 of the Fair Value Hierarchy

The following table summarizes amounts transferred into Level 3 of the fair value hierarchy during the year ended December 31, 2024:

 

 

 

Year Ended December 31,

 

 

 

2024

 

 

2023

 

Beginning balance

 

$

 

 

$

 

Transfer in

 

 

906

 

 

 

 

Unrealized gain

 

 

(632

)

 

 

 

Ending balance

 

$

274

 

 

$

 

Amount of unrealized gain for the period included in income relating to liabilities at the end of the reporting period

 

$

(632

)

 

$